Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
Date:2/17/2011

a non-GAAP adjusted EBITDA measure will be utilized, which is more aligned with management's internal goal setting process.  Non-GAAP information under the previous methodology for the fourth quarter and years ended 2010 and 2009, as well as the new adjusted EBITDA methodology for fiscal 2010 and guidance for 2011 is denoted on page 5 of this press release.  In addition, this non-GAAP adjusted EBITDA information has been provided on a pro-forma basis for the quarters and fiscal years for 2009 and 2010 in Appendix A for information purposes.   Anticipated Upcoming Milestones2Q 2011: Initiation of pivotal Phase III trial for Firdapse for LEMS in the U.S.Mid-2011: Top-line results from PEG-PAL Phase II trial, including daily dosing and formulation studiesLate 2011: 510k approval and commercial availability of the handheld blood Phe monitor for PKU1Q 2012: Initiation of Phase III PEG-PAL trial1Q 2012: Initiation of Phase I trial for BMN-111 for Achondroplasia1H 2012: NDA filing for Firdapse for LEMS in the U.S.2H 2012: Top-line results for Phase III trial for GALNS for MPS IVA2H 2012: Top-line results for PKU-016 Kuvan neurocognitive study4Q 2012: Approval of Firdapse for LEMS in the U.S.4Q 2012: Top-line results for Phase I/II trial for BMN-701 for Pompe disease4Q 2012/1Q 2013: Market authorization application filings for GALNS for MPS IVAResearch and Development ProgramsBioMarin continues to make significant investments in research and development to ensure continued growth of the company.  The current pipeline includes programs in various stages of development and is focused on treating a range of serious unmet medical needs.Advanced Clinical Programs

  • GALNS for MPS IVA: BioMarin initiated a randomized, double-blind, placebo-controlled Phase III study in early February 2011 with primary endpoint of six-minute walk distance, 24 weeks in treatment duration and treatment doses of two mg/kg/week and two mg/kg/every other week.  
    '/>"/>

  • SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
    2. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
    3. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
    4. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
    5. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
    6. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
    7. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
    8. BioMarin Announces Third Quarter 2010 Financial Results
    9. BioMarin to Host a Research and Development Day on October 19th
    10. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
    11. BioMarin to Present at the UBS Global Life Sciences Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... June 30, 2014. Financial Results for the Six ... revenue for the quarter ended June 30, 2014 increased to ... 30, 2013 primarily due to IMBRUVICA ® (ibrutinib) net ... for the six months ended June 30, 2014 increased to ...
    (Date:7/31/2014)... -- UBM Medica US announces that Cancer Network ... exclusive slide shows dealing with communication in the oncology ... Cancer Network, the online home ... and podcasts about the latest clinical findings. Among the ... , End-of-life care is challenging for even the most ...
    (Date:7/31/2014)... -- Touro University California,s College of Pharmacy is pleased ... of a $150,000 grant by the Joseph & Vera ... research and classroom space on its campus. ... of health sciences, and will help us apply high-tech ... our students," said Shelley Berkley , CEO and ...
    Breaking Medicine Technology:Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Touro University California Garners Grant From Long Foundation 2
    ... (OTC: HEWA) a leading VIPPS accredited retail mail-order pharmacy, ... ended September 30, 2011. In the ... increased $1,567,764 to $2,783,240, up 129% compared to the ... strength in its prescription business.  Prescriptions filled increased from ...
    ... Nov. 17, 2011 Cohera Medical, a rapidly growing ... selling its lead product, TissuGlu® Surgical Adhesive, to hospitals ... regional launch will document and highlight the advantages of ... expansion throughout Germany and to additional European markets in ...
    Cached Medicine Technology:HealthWarehouse.com Reports 129% Quarter-Over-Quarter Revenue Growth in the Third Quarter 2011 2Cohera Medical Commercializes TissuGlu® Surgical Adhesive in Germany 2Cohera Medical Commercializes TissuGlu® Surgical Adhesive in Germany 3
    (Date:8/1/2014)... NY (PRWEB) August 01, 2014 Ticket Down ... at Maple Lane Farms in Knoxville/Greenback, TN; Ingram Farms ... Whitehurst Cattle Farm in Archer/Gainesville, FL. Luke Bryan is currently ... with Lee Brice and Cole Swindell. Bryan is responsible for ... world each summer and this year, just because the summer ...
    (Date:8/1/2014)... at the Institute of Bioengineering and Nanotechnology (IBN), ... Singapore (NCCS) have co-developed the first molecular test ... in kidney cancer patients. This breakthrough was recently ... top urology journal. , According to IBN ... our expertise in molecular diagnostics and cancer research, ...
    (Date:8/1/2014)... CapsCanada, a leading provider of ... new K-CAPS® (HPMC capsules) manufacturing facility in Lakeshore, ... last year while experiencing growing global demand for ... “KCAPS® are currently sold in more than 60 ... to other HPMC capsules, K-CAPS® have exceptional appearance ...
    (Date:8/1/2014)... Hills, CA (PRWEB) August 01, 2014 ... has found that carbohydrates may contribute to the ... genetically predisposed to the disease. The study was authored ... it, carbohydrates were found to cause intestinal cells to ... more susceptible to colorectal cancer. , “What’s interesting ...
    (Date:8/1/2014)... South Jordan, Utah (PRWEB) August 01, 2014 ... selling company MonaVie, who completes its 500th week of ... paid since the company was founded in January 2005 ... 39 countries throughout the world. The company pays commissions ... HKD, HUF, ILS, JPY, MYR, MXN, NZD, PLN, USD, ...
    Breaking Medicine News(10 mins):Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 3Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 4Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3Health News:Carbs May Contribute to Colon Cancer 2Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2
    ... mice has found that though they do not develop zits, ... to differentiate the cells// in the sebaceous glands that are ... sebaceous gland is formed. ,In new research, published ... Howard Hughes Medical Institute investigator at Rockefeller University, settles this ...
    ... review of the performance of the 14 boards against ... nutritional care finds// too little progress is being made ... had issued advice including recommendations that patients should be ... 24 hours of being admitted following concerns about the ...
    ... amounts of soda and sugary drinks is making the ... Hu and his colleagues at the Harvard School of ... conducted over the last 40 years. ,They ... American diet come from added sweeteners. And sweeteners in ...
    ... second-year students at Wake Forest University School of Medicine ... nervous system. Instead, a semi-conscious,// vomiting “patient” was rolled ... to help manage the case. ,“SimMan?,” a ... typical mannequin. The simulated patient makes realistic heart, lung, ...
    ... Text messages between lovers was imitated by a government AIDS ... highest HIV rates. This enraged activists// who feel it suggests ... ,Pictures of a mobile phone screen bearing text messages like ... over now, my husband is out' features in the 'Makhwapheni ...
    ... local newspaper, Vietnam News, inns are to be allowed to sell ... ,As a measure to reduce risks, Vietnam will allow the sales ... come into effect from Jan. 1, 2007. Presently, condom sales and ... in many of these inns. ,Apart from the prostitutes ...
    Cached Medicine News:Health News:'Blimp1' Gene Linked To Oily Skin 2Health News:Computerized Patient Used to Teach Science to Medical Students 2Health News:AIDS Campaign Enrages HIV Infected Swazis 2
    The Ultima 2000 SE is flexible in meeting the needs of both office and operating room use. It is the answer for the clinical practice with a wide range of ophthalmic demands looking for minimal risk ...
    Practice-oriented ophthalmic laser systems for photodisruption....
    Magnetic Farnsworth D15 kit Magnets move the color disks. Protects disks from fingerprints. Keeps all the disks in one place. Clear glass insures accurate color perception. Makes color testing fun....
    ... D15 test is used to ... defect vs normal. Farnsworth D15 ... permit the patient to select ... the box is closed and ...
    Medicine Products: